Objective: Prospective data on the use of granulocyte-colony-stimulating factor (G-CSF) in non-Hodgkin's lymphoma and its aggressive subtypes, including diffuse large B-cell lymphoma (DLBCL), are limited. MONITOR-GCSF is a pan-European, multicenter, prospective, observational study aiming to describe treatment patterns and clinical outcomes in patients receiving biosimilar filgrastim in the prophylaxis of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN).
| INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL), with a crude incidence rate of 3.8 per 100 000 people each year in Europe. 1 The current standard of care for DLBCL comprises combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone plus immunotherapy with the humanised monoclonal antibody directed at CD20, rituximab (R-CHOP). 2 This regimen yields 5-and 10-year survival rates of 51% and 45%, respectively, 3, 4 but is associated with a significant risk of chemotherapy-induced neutropenia (CIN)/febrile neutropenia (FN), a complication of myelotoxic chemotherapy that can markedly decrease quality of life and increase healthcare costs. 5 Clinical trials have shown that up to 50% of patients who receive R-CHOP experience CIN/FN, which can result in dose delays or reductions that can adversely impact patient outcomes. 6 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. solid or haematologic malignancies have already been reported. 13 Here, we describe patient characteristics, treatment patterns and outcomes for the cohort of patients with DLBCL who received primary or secondary prophylaxis with biosimilar filgrastim as part of routine clinical practice. We also present results for patients aged ≥65 years and ≥70 years.
| METHODS

| Design
The background and methodology of MONITOR-GCSF have previously been described elsewhere. [13] [14] [15] Briefly, MONITOR-GCSF was a pan-European, prospective, observational, multilevel, pharmacoepidemiological study of chemotherapy-treated cancer patients who III or IV DLBCL were eligible for inclusion if they were scheduled to receive 42% (103) patients (2%). R-CHOP-21 was the most commonly prescribed chemotherapy regimen in patients aged ≥65 and ≥70 years, followed
by CHOP-21 and R-PMitCEBO. Of the seven patients treated with R-PMitCEBO, all but one were aged ≥70 years.
| Prophylaxis
Data on biosimilar filgrastim prophylaxis were available for 239 patients with DLCBL, including 123 aged ≥65 years and 94 aged ≥70 years (Table 3) . Reasons for discontinuation of prophylaxis with biosimilar filgrastim and for switching to other G-CSF included "change of G-CSF,"
"unavailability of drug in the hospital," "stopping chemotherapy" and "cancellation of the chemotherapy protocol." 
| Clinical outcomes
| Safety
The most frequent AE reported in patients with DLBCL was bone pain, followed by arthralgia and back pain (Table 5 ).
| DISCUSSION
This analysis described patient characteristics, treatment patterns and clinical outcomes for patients with DLBCL who received primary or secondary prophylaxis with biosimilar filgrastim as part of routine clinical practice in the MONITOR-GCSF observational study.
| Prevention of chemotherapy-induced neutropenia
Of the patients with DLBCL included in MONITOR-GCSF, patients had a mean age of 62.7 years, with 51% of patients aged ≥65 years and 39.2% of patients aged ≥70 years. In line with guideline recommenda- 
| Prevention of febrile neutropenia
In MONITOR-GCSF, the percentage of patients experiencing FN (any grade) was higher in patients with DLBCL (9.8%) compared with the overall population (5.9%). In Cycle 1, FN was reported in 2.4% patients
T A B L E 2 Frequent chemotherapy regimens (>3 patients) in patients with DLBCL in the MONITOR-GCSF study
Chemotherapy regimen
All patients (n = 245), n (%) 
T A B L E 3 G-CSF prophylaxis in patients with DLBCL included in the MONITOR-GCSF study
Patient group Mean (SD) dose (μg) Median dose (min, max) Discontinued prophylaxis, n (%) Used another G-CSF
| Real-world data
A US retrospective observational study described the incidence of grade 3/4 neutropenia, patterns of G-CSF use and incidence of chemotherapy dose delays, dose reductions and reduced relative dose intensity (RDI) among 1,579 patients <65 and ≥65 years who received CHOP-based chemotherapy for NHL. 18 Most patients (86.9%) received G-CSF; however, compared to the MONITOR-GCSF study, a substantial proportion (57.4%) had documented grade 3/4 neutropenia. Dose delays and reduced RDI were common across all ages of patients with NHL receiving CHOP-based chemotherapy, but patients ≥65 years had a 24.9% incidence of dose reductions, which was higher than that reported in patients <65 years (9.6%), and also higher than in patients ≥65 years in MONITOR-GCSF (10.4%-12.5%). All patients who were indicated for G-CSF support received it in MONITOR-GCSF; however, both younger and older patients often fail to receive any or optimum G-CSF prophylaxis in clinical practice, 11 despite guideline recommendations. 1, 8, 19 Maintaining a CHOP RDI of >90% has been shown to improve overall survival in DLBCL. As such, better adherence to guidelines for the use of prophylactic G-CSF during chemotherapy could improve the outcome and care of patients with DLBCL. 
| Safety profile
The most frequent AE reported in patients with DLBCL was bone pain; however, this AE was experienced at lower levels compared with the overall study population (2.9% vs 24.7%). The reasons for this difference is unclear, although a low reported incidence may reflect the fact that bone pain is a widely recognised AE associated with use of G-CSF and, therefore, less likely to be reported in long-term observational studies. 20 Indeed, bone pain was reported in 5.6% of patients in the HEXAFIL study 17 and in 8.2% of a French observational study. 21 Regarding randomised controlled studies with DLBCL, musculoskeletal pain was reported in 2.6% 16 and 7.1% 3 of patients. These incidences are lower than those reported in other studies of filgrastim; for example, incidences of 26%-42% have been reported in patients with breast cancer. [22] [23] [24] [25] [26] It should be noted that differences may be due to different types of cancer and the chemotherapy regimen used, as well as variations in the recording of AEs and how bone/musculoskeletal pain was defined. International GmbH.
| CONCLUSION
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